ESMO TAT 2022 | DNA damage repair pathways and WEE1 as possible therapeutic targets in SCLC

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the genetics behind small-cell lung cancer (SCLC) and the identification of novel therapeutics targets that are related to the cell cycle. In SCLC, cell cycle regulation is highly unstable, with one of the two checkpoints no longer functioning correctly. DNA damage repair pathways provide interesting therapeutic targets for SCLC, as they have a large impact on the cell cycle. Dr Sen also explains the potential of WEE1, a master regulator of the cell cycle checkpoint. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.